Tweet
J Infect Chemother
. 2025 Apr 16:102708.
doi: 10.1016/j.jiac.2025.102708. Online ahead of print. Long-term functional prognosis with tocilizumab in severe COVID-19 infection: A multicenter prospective observational study on mechanically ventilated ICU patients in the COVID-19 Recovery Study II
Junji Hatakeyama 1 , Kensuke Nakamura 2 , Naoki Kanda 3 , Akira Kawauchi 4 , Shigeki Fujitani 5 , Taku Oshima 6 , Hideaki Kato 7 , Kohei Ota 8 , Hiroshi Kamijo 9 , Tomohiro Asahi 10 , Yoko Muto 11 , Miyuki Hori 11 , Arisa Iba 11 , Mariko Hosozawa 11 , Hiroyasu Iso 11
Affiliations
Background: Tocilizumab, an IL-6 receptor antagonist, may prevent functional impairments in critically ill patients by attenuating the cytokine storm. This study investigated a potential effect of tocilizumab on preventing functional impairments in patients with severe coronavirus infection 2019 (COVID-19).
Methods: In a multicenter prospective observational study, patients with COVID-19 ≥20 years requiring mechanical ventilation admitted to the intensive care unit between April 2021 and September 2021 and discharged alive were followed for one year. A self-administered questionnaire on sequelae and functional impairments was mailed in August 2022, and data were collected. A multivariate logistic regression was used to assess the impact of tocilizumab on physical function, mental health, and Long COVID.
Results: Of 157 analyzed patients, 41 received tocilizumab. The tocilizumab group had more severe illness, but a lower prevalence of physical impairment (17.1% vs. 23.3%, p = 0.41) and mental disorders (19.5% vs. 39.7%, p = 0.009) than the non-tocilizumab group. The prevalence of Long COVID was higher in the tocilizumab group (92.7% vs. 80.2%, p = 0.06), whereas fatigue/malaise was significantly lower (19.5% vs. 37.1%, p = 0.039). Adjusted odds ratios (95% confidence interval) for physical impairment, mental disorders, and Long COVID with tocilizumab were 0.70 (0.2 to 2.1), 0.40 (0.16 to 1.01), and 2.94 (0.7 to 12.3), respectively, with no significant difference.
Conclusions: Tocilizumab was associated with a lower prevalence of physical impairment and mental disorders at 1 year in patients with severe COVID-19. Furthermore, Long COVID had a weaker impact on physical and cognitive functions.
Keywords: COVID-19; IL-6 receptor antagonist; Long COVID; functional disability; post-intensive care syndrome; tocilizumab.
. 2025 Apr 16:102708.
doi: 10.1016/j.jiac.2025.102708. Online ahead of print. Long-term functional prognosis with tocilizumab in severe COVID-19 infection: A multicenter prospective observational study on mechanically ventilated ICU patients in the COVID-19 Recovery Study II
Junji Hatakeyama 1 , Kensuke Nakamura 2 , Naoki Kanda 3 , Akira Kawauchi 4 , Shigeki Fujitani 5 , Taku Oshima 6 , Hideaki Kato 7 , Kohei Ota 8 , Hiroshi Kamijo 9 , Tomohiro Asahi 10 , Yoko Muto 11 , Miyuki Hori 11 , Arisa Iba 11 , Mariko Hosozawa 11 , Hiroyasu Iso 11
Affiliations
- PMID: 40250803
- DOI: 10.1016/j.jiac.2025.102708
Background: Tocilizumab, an IL-6 receptor antagonist, may prevent functional impairments in critically ill patients by attenuating the cytokine storm. This study investigated a potential effect of tocilizumab on preventing functional impairments in patients with severe coronavirus infection 2019 (COVID-19).
Methods: In a multicenter prospective observational study, patients with COVID-19 ≥20 years requiring mechanical ventilation admitted to the intensive care unit between April 2021 and September 2021 and discharged alive were followed for one year. A self-administered questionnaire on sequelae and functional impairments was mailed in August 2022, and data were collected. A multivariate logistic regression was used to assess the impact of tocilizumab on physical function, mental health, and Long COVID.
Results: Of 157 analyzed patients, 41 received tocilizumab. The tocilizumab group had more severe illness, but a lower prevalence of physical impairment (17.1% vs. 23.3%, p = 0.41) and mental disorders (19.5% vs. 39.7%, p = 0.009) than the non-tocilizumab group. The prevalence of Long COVID was higher in the tocilizumab group (92.7% vs. 80.2%, p = 0.06), whereas fatigue/malaise was significantly lower (19.5% vs. 37.1%, p = 0.039). Adjusted odds ratios (95% confidence interval) for physical impairment, mental disorders, and Long COVID with tocilizumab were 0.70 (0.2 to 2.1), 0.40 (0.16 to 1.01), and 2.94 (0.7 to 12.3), respectively, with no significant difference.
Conclusions: Tocilizumab was associated with a lower prevalence of physical impairment and mental disorders at 1 year in patients with severe COVID-19. Furthermore, Long COVID had a weaker impact on physical and cognitive functions.
Keywords: COVID-19; IL-6 receptor antagonist; Long COVID; functional disability; post-intensive care syndrome; tocilizumab.